Subscribe
Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.
Oral Gepants: Christopher Gottschalk, MD Tells the Origin Story, Highlights Broad Efficacy
Atogepant: Pivotal Phase 3 Study Meets Primary Endpoint for Preventive Treatment of Chronic Migraine
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific Preventive Therapies Can Be a Primary Care Tool, Leading Investigator Says
Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH
Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD
Jacob Sands, MD; Beth Sandy, MSN, CRNP, FAPO; Stephanie McDonald, FNP-BC, AOCNP
John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD
Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MSc, FASN
Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD
Eytan M. Stein, MD; Marina Kremyanskaya, MD, PhD; Hannah Levavi, MD
Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO
Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD
Rami Komrokji, MD; Maen Hussein, MD